Discrimination of agonist-antagonist opioids in humans trained on a two-choice saline-hydromorphone discrimination
- PMID: 1373189
Discrimination of agonist-antagonist opioids in humans trained on a two-choice saline-hydromorphone discrimination
Abstract
The stimulus properties of four opioid agonist-antagonists were assessed in postaddict volunteers trained in a two-choice drug discrimination procedure to discriminate between the effects of i.m. saline and hydromorphone (3 mg/70 kg). Behavioral, subjective and physiological measures were concurrently collected. After training, generalization curves were determined for hydromorphone, pentazocine, butorphanol, nalbuphine and buprenorphine. In generalization testing, hydromorphone produced dose-related increases in hydromorphone-appropriate responses and in characteristic opioid agonist-like subjective effects measures. In general, each of the study drugs produced a profile of subjective and physiological effects similar to that reported in other human studies. These subjective indices showed the study drugs to be heterogeneous. However, in this two-choice drug discrimination procedure, they were discriminated as homogeneous (i.e., all were discriminated as hydromorphone-like). The present study also found that all test drugs were subjectively identified as being opiates, and all were subjectively rated as similar to the hydromorphone training condition. A previous three-choice discrimination was sensitive to the heterogeneity among these drugs on both the discrimination measures and subjective ratings of similarity to the hydromorphone training condition. Thus, the specific procedures of drug discrimination studies may have an effect on some subjective indices, although this interaction is not apparent for the majority of subjective effect measures. Also, the characterization of opioids in drug discrimination testing appears to depend upon the specific training subjects receive; this is most clear with discrimination measures, and to a more limited extent, with subjective measures.
Similar articles
-
Drug discrimination assessment of agonist-antagonist opioids in humans: a three-choice saline-hydromorphone-butorphanol procedure.J Pharmacol Exp Ther. 1994 Oct;271(1):48-60. J Pharmacol Exp Ther. 1994. PMID: 7525929
-
Assessment of opioid partial agonist activity with a three-choice hydromorphone dose-discrimination procedure.J Pharmacol Exp Ther. 1999 Jun;289(3):1350-61. J Pharmacol Exp Ther. 1999. PMID: 10336526
-
Effects of agonist-antagonist opioids in humans trained in a hydromorphone/not hydromorphone discrimination.J Pharmacol Exp Ther. 2000 Oct;295(1):114-24. J Pharmacol Exp Ther. 2000. PMID: 10991968
-
Assessment of buprenorphine in a drug discrimination procedure in humans.NIDA Res Monogr. 1992;121:28-37. NIDA Res Monogr. 1992. PMID: 1406908 Review.
-
Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).Pain Pract. 2008 Jul-Aug;8(4):287-313. doi: 10.1111/j.1533-2500.2008.00204.x. Epub 2008 May 23. Pain Pract. 2008. PMID: 18503626
Cited by
-
Progesterone effects on the discriminative stimulus, subjective and performance effects of triazolam in healthy, premenopausal women.Behav Pharmacol. 2011 Sep;22(5-6):441-9. doi: 10.1097/FBP.0b013e328349fc02. Behav Pharmacol. 2011. PMID: 21808190 Free PMC article. Clinical Trial.
-
Core outcome measures for opioid abuse liability laboratory assessment studies in humans: IMMPACT recommendations.Pain. 2012 Dec;153(12):2315-2324. doi: 10.1016/j.pain.2012.07.035. Epub 2012 Sep 19. Pain. 2012. PMID: 22998781 Free PMC article.
-
Buprenorphine: an analgesic with an expanding role in the treatment of opioid addiction.CNS Drug Rev. 2002 Winter;8(4):377-90. doi: 10.1111/j.1527-3458.2002.tb00235.x. CNS Drug Rev. 2002. PMID: 12481193 Free PMC article. Review.
-
Substitution profile of Delta9-tetrahydrocannabinol, triazolam, hydromorphone, and methylphenidate in humans discriminating Delta9-tetrahydrocannabinol.Psychopharmacology (Berl). 2009 Apr;203(2):241-50. doi: 10.1007/s00213-008-1393-3. Epub 2008 Nov 19. Psychopharmacology (Berl). 2009. PMID: 19018520 Free PMC article.
-
Buprenorphine-containing treatments: place in the management of opioid addiction.CNS Drugs. 2006;20(9):697-712. doi: 10.2165/00023210-200620090-00001. CNS Drugs. 2006. PMID: 16953647 Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Other Literature Sources